{
  "report_rows": [
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2,530M vs. cons $2,455.5M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "SYFOVRE + EMPAVELI Combined (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$100M vs. cons $88.95M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.10 vs. cons $1.97",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Total Revenue (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$10.2-10.4B vs. cons $10,032.9M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Non-GAAP EPS (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide range straddles cons ~$12.60",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Apellis Growth Trajectory (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide high-teen to low-20% growth vs. cons implying mid-teen%",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 3.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 estimate revisions track the FY revenue raise; Q3 IPR&D charge already disclosed and will not drag; archetype A 5-day avg +4.22%",
  "day5_confidence": "MEDIUM"
}